Related Experiment Video

Updated: May 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Monoclonal antibody-related drugs for cancer therapy

G N Li1, S P Wang, X Xue

  • 1Shandong Luye Pharmaceutical Group Co., Ltd., Yantai, Shandong, China.

Drug Discoveries & Therapeutics
|November 26, 2013
PubMed

Insights

Recent advances in cancer treatment leverage molecular markers on tumor cells. Monoclonal antibodies (mAbs) and antibody-drug conjugates offer targeted therapies for malignancies, improving cancer care.

Area of Science:

  • Oncology
  • Immunotherapy
  • Drug Development

Background:

  • Significant advancements in malignancy treatment have occurred over recent decades.
  • Cancer cells often express unique molecular markers not found on normal cells.
  • These markers are crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To review recent progress in antibody-based cancer therapies.
  • To focus on the evolution and current applications of antibody drugs in oncology.
  • To briefly describe the development of antibody-drug conjugates.

Main Methods:

  • Review of scientific literature on antibody-based cancer treatments.
  • Analysis of the role of molecular markers in drug design.
  • Examination of the progression of antibody drugs and antibody-drug conjugates.

Main Results:

  • Monoclonal antibodies (mAbs) and related antibody drugs represent effective targeted cancer therapies.
  • The identification of specific molecular markers on cancer cells guides drug development.
  • Antibody-drug conjugates are an emerging area in targeted cancer treatment.

Conclusions:

  • Targeted therapies using monoclonal antibodies (mAbs) have significantly advanced cancer treatment.
  • Future cancer therapeutics will likely involve further development of antibody-based strategies, including conjugates.
  • The specificity of molecular markers on cancer cells is key to successful targeted drug design.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K